Madison Weisz

Vice President, Medicus Pharma

Role: Vice President at Medicus Pharma Ltd
Location: Philadelphia, PA, US
LinkedIn followers: 500 followers

General Business & ManagementView LinkedIn profile

Experience

Vice President
Medicus Pharma Ltd
Apr 2024 — Present

Education

The Baldwin School
High School Diploma
2013 — 2017
The George Washington University
Master of Science - MS
2021 — 2022
Fox School of Business at Temple University
Economics
2018 — 2021

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@medicuspharma.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Medicus Pharma Ltd

Biotechnology Research · 16 employees · Founded 2023

Medicus Pharma Ltd.(NASDAQ:MDCX) is a precision guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutic assets designed to transform the standard of care. The company is actively engaged in multiple countries spread over three continents. Our strategy is to advance select programs through Phase 2 proof-of-concept and pursue licensing or strategic partnerships with established pharmaceutical companies that are best positioned to conduct late-stage development and commercialization. Our Phase 2 studies are designed to generate decision-grade clinical, regulatory and operational data packages intended to support partnering discussions and potential licensing transactions. We look into opportunities where an unmet need exists for improved patient safety and efficacy. The Company is currently advancing the clinical development program of its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC). Medicus is also developing Teverelix, a next generation GnRH Antagonist as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer. D-MNA and Teverelix, collectively represent ~$8 billion in potential market opportunity.

medicuspharma.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Experience

Vice President

Education

The Baldwin School

The George Washington University

Fox School of Business at Temple University

Find verified contacts for anyone on LinkedIn